购物车
- 全部删除
- 您的购物车当前为空
Chiglitazar is a dual agonist of PPARα/γ (EC50s: 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ).
为众多的药物研发团队赋能,
让新药发现更简单!
Chiglitazar is a dual agonist of PPARα/γ (EC50s: 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ).
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 1,600 | 5日内发货 | |
5 mg | ¥ 2,710 | 5日内发货 | |
25 mg | ¥ 9,620 | 6-8周 | |
50 mg | ¥ 12,500 | 6-8周 | |
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | Chiglitazar is a dual agonist of PPARα/γ (EC50s: 1.2, 0.08, and 1.7 μM for PPARα, PPARγ, and PPARδ). |
靶点活性 | PPARγ:0.08 μM (EC50), PPARα:1.8 μM (EC50), PPARδ:1.7 μM (EC50) |
体外活性 | Chiglitazar shows weaker PPARγ activating activity than rosiglitazone, but stronger than pioglitazone. In terms of PPARα activation, Chiglitazar shows a more potent activity than rosiglitazone, pioglitazone, or WY14643 which is a selective PPARα agonist [1]. |
体内活性 | Plasma glucose levels in the MSG rats treated with Chiglitazar or rosiglitazone are significantly reduced compared with the control group treated with the vehicle, after insulin injection. Fasting PI levels are lower in animals treated with Chiglitazar and rosiglitazone than control. Chiglitazar ameliorates the HOMA indices. For IPGTT, at the 30?min after glucose loading, the glucose values in the 5 and 10?mg/kg Chiglitazar and rosiglitazone-treatment groups are significantly lower than those in the vehicle treatment group [1]. |
分子量 | 572.62 |
分子式 | C36H29FN2O4 |
CAS No. | 743438-45-1 |
密度 | 1.25 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容